Journal of International Psychiatry

[Abstract] Background: Clozapine, a second-generation atypical antipsychotic, has excellent efficacy in the treatment of schizophrenia, especially refractory schizophrenia, but the use of clozapine in some schizophrenia patients may lead to cardiotoxicity such as myocarditis, cardiomyopathy, and arrhythmia. At present, there is no clear conclusion on the pathogenesis, diagnostic basis, re-initiation of clozapine-associated myocarditis, and its treatment. OBJECTIVE: This article summarises the progress of clozapine-induced myocarditis in patients with schizophrenia, in order to better guide the use of clozapine. CONCLUSION: There is no clear diagnostic and therapeutic standard for clozapine-associated myocarditis, but clozapine-associated myocarditis can be reintroduced in schizophrenic patients under careful and prudent supervision, and electroconvulsive therapy (ECT) combined with pharmacological treatment of clozapine-associated myocarditis may be a good method. Translated with DeepL.com (free version)

Clozapine;Clozapine-associated myocarditis